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Alzheimer’s disease (AD) aff  ects more than 12 
million patients worldwide, and it accounts for 
most of the dementia diagnosed after the age of 
60. The disease is clinically manifested by a glo-
bal decline of cognitive function that progresses 
slowly. The characteristic features of AD brains 
are the formation of neurofi  brillary tangles and 
the presence of senile plaques, the neurotoxic-
ity of which are believed to be responsible for the 
neuronal loss and the degeneration of the cho-
linergic system in AD patients (1, 2). β-Amyloid 
(Aβ), which is the major extracellular component 
of the senile plaques, is generated from cleavage 
of the amyloid precursor protein, a transmem-
brane protein, to an amyloidogenic end prod-
uct (3). The amount of Aβ needed to form the 
plaques correlates with the degree of neuronal 
damage and cognitive defi  cits (1, 2).
No treatments can stop AD today. Most of 
the current clinical treatments for AD are largely 
symptomatic, including the use of acetylcho-
linesterase inhibitors to improve cognitive abil-
ity and psychotropic drugs to modify patient 
behaviors (4). Treatments that focus on delay-
ing the onset of symptoms and slowing the rate 
of disease progression are also being used. These 
strategies enhance the functions of the survival 
neuronal cells, and they include the uses of (a) 
tacrine, the fi  rst Food and Drug Administration–
approved drug for AD therapy; (b) memantine, 
an N-methyl-d-aspartate antagonist; and (c) anti-
oxidants such as vitamin E. Other likely prom-
ising therapies for AD include antiamyloid 
immunotherapy, amyloid vaccination, and the 
use of secretase inhibitors that prevent the for-
mation of Aβ and neurofi  brillary tangles (5). 
However, these therapies could all cause side 
eff  ects and, consequently, clinical problems (4–6). 
AD is also one of the candidate diseases for 
the development of cell-regenerative strategies, 
because the transplantation of cells lacking the 
AD-causing mutation could replace the lost 
neurons and reconstitute the damaged neuro-
nal connections.
G-CSF is a hematopoietic growth factor 
named for its role in the proliferation and dif-
ferentiation of cells of the myeloic lineage. Ad-
ministration of G-CSF mobilized hematopoietic 
stem cells (HSCs) from the bone marrow into 
the peripheral blood (7). The peripheral blood–
derived HSCs have been used in place of bone 
marrow cells in transplantation for the regener-
ation of nonhematopoietic tissues such as skel-
etal muscle and the heart (8). G-CSF has been 
used extensively for >10 yr in the treatment of 
chemotherapy-induced neutropenia, as well as 
for bone marrow reconstitution and stem cell 
mobilization (9, 10). More recently, it has been 
shown that administration of G-CSF in stroke 
mouse models could induce neurogenesis near 
the damaged area of these mice, leading to neuro-
logical and functional recovery (11–13).
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In view of these properties of G-CSF and its potential ap-
plications in the treatment of diseases with neuronal damages, 
two diff  erent Aβ aggregate–induced AD mouse models were 
used to explore the possibility that G-CSF might be applied 
for therapy of AD. Interestingly, we found that G-CSF in-
duced stem cell release from the bone marrow, stimulated 
neurogenesis surrounding the Aβ plaques in mouse brains, and 
substantially improved the neurological function of AD mice.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
G-CSF improved the neurological behavior of an acutely 
induced AD mouse model
Two diff  erent Aβ aggregate–induced AD mouse models 
were used to explore the possibility that G-CSF might be 
applied for therapy of AD. To set up an acutely induced 
AD model (14, 15), the protocol described in Fig. 1 A was 
followed. Mice were fi  rst trained in the Morris water maze 
task. 7 d later, aggregated Aβ was injected into the junction 
of the hippocampus and cortex of the mouse brains. Another 
7 d were allowed for the injected mice to develop AD-like 
features (Fig. 1 A). As indicated by immunostaining with 
anti-Aβ (Fig. 1 B) and by staining with thiofl  avin S (Fig. 
1 C), which identifi  ed the locations of the Aβ aggregates 
(14, 15), the Aβ aggregates indeed formed near the sites of 
injection in the mouse brains. At the same time, a behav-
ior test using the Morris water maze task showed that mice 
receiving the Aβ injection were impaired in their learning/
memory abilities (Fig. 1 D). To evaluate whether G-CSF 
could rescue the neurological defects of the Aβ-induced AD 
mice, the water maze task was again used to test the AD mice 
after injection with G-CSF or PBS, respectively, for 5 d (Fig. 
1 A). As shown in Fig. 1 E, the latency of G-CSF–treated AD 
mice was signifi  cantly less than the PBS-treated AD mice. In 
fact, it was similar to those of the control mice injected with 
either G-CSF or PBS (Fig. 1 E). These data indicated that 
subcutaneous administration of G-CSF signifi  cantly restored 
the learning/memory function of mice with acutely induced 
AD features.
G-CSF stimulated stem cell mobilization and homing 
in the brains of AD mice
In previous experiments, it was found that G-CSF treatment 
stimulated the release of HSCs into blood circulation (7). 
Furthermore, proliferating cells accumulated near the dam-
aged tissue regions, which likely contributed to the recovery 
from ischemic heart disease or stroke (8, 11). To examine 
whether similar events occurred in the acutely induced AD 
mice treated with G-CSF, we initially analyzed the blood 
cell counts of these mice in comparison to the controls. 
Figure 1.  G-CSF treatment of an acutely induced mouse AD 
model. (A) Experimental design for the G-CSF treatment of an acutely 
induced mouse AD model. Starting from the fi  rst day (−7), the mice re-
ceived behavioral training for six sessions in 3 d to learn the location of a 
submerged platform in the pool. The mice were then subjected to stereo-
taxic surgery for the injection of aggregated Aβ on day 0. 7 d after the 
Aβ injection, the water maze test (six sessions from days 8–10) was used 
to confi  rm the AD symptoms of the injected mice. Subsequently, the mice 
were injected subcutaneously with 50 μg/kg G-CSF once daily for 5 con-
secutive days (days 10–14). At the same time, they received daily intra-
peritoneal injections of 50 mg/kg BrdU for 16 consecutive days (days 
10–25). The water maze test was next used to check the behavioral per-
formance of mice (days 23–25). Finally, the mice were killed, and their 
brains were analyzed by immunohistochemistry. (B) Aβ staining (brown) 
of an AD mouse brain 7 d after the Aβ injection. The arrow points to the 
site of injection. (C) Thiofl  avin S staining of the Aβ deposits of another AD 
mouse brain 7 d after the Aβ injection. The arrow indicates the site of 
injection. Bars, 200 μm. (D) Mice injected with Aβ or PBS were subjected 
to the Morris water maze learning test 7 d after the injection. The learning/
memory capabilities are expressed as the latencies exhibited in six 
  consecutive sessions of the test (n = 20 for each group). (E) The latencies 
of AD and control mice with subcutaneous administration of G-CSF and 
PBS, respectively, as measured from the water maze learning task, are 
examined (n = 10 for each of the four groups). Data are means ± SEM. 
*, P < 0.05. DG, dentate gyrus.JEM VOL. 204, June 11, 2007  1275
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Indeed, animals treated for 5 d with G-CSF exhibited a sig-
nifi  cant increase in their white blood cells (WBCs; Fig. 2 A) 
but not in their red blood cells or platelets (not depicted), 
suggesting that our G-CSF treatment of the mice also mo-
bilized HSCs into their peripheral blood. We then used the 
cell-proliferation marker BrdU to follow the possible en-
graftment of G-CSF–mobilized HSCs in the brain (11, 12). 
As represented in Fig. 2 (B and C), a signifi  cant increase in 
BrdU+ cells was observed in the brains of G-CSF–treated 
mice in contrast to those injected with PBS (Fig. 2 D). Fur-
thermore, the BrdU+ cells in the brains of AD mice treated 
with G-CSF are more concentrated near the Aβ aggregates, 
with decreased numbers radially distant from the sites of in-
jection (Fig. 2 E).
Finally, it is known that administration of G-CSF mainly 
mobilizes CD34+ HSCs from the bone marrow into the pe-
ripheral blood (16). To test whether the BrdU+-proliferating 
cells observed in the brains of G-CSF–treated AD mice were 
derived from HSCs, double immunostaining with anti-BrdU 
and anti-CD34 was performed. As represented in Fig. 2 F, 
 20% of the BrdU+ cells in the cortex and hippocampus co-
expressed CD34. The data in Fig. 2 indicated that injection 
of G-CSF into the acute, Aβ-induced AD mice mobilized 
the release of HSCs into the peripheral blood, and it signifi  -
cantly stimulated the increase of proliferating cells surround-
ing the Aβ aggregates that formed near the injection sites 
of Aβ.
G-CSF also improved the neurological behavior of a chronic 
AD mouse model, Tg2576
The second AD mouse model we used to test the therapeutic 
eff  ect of G-CSF was Tg2576. Tg2576 mice overexpressed the 
human amyloid precursor protein with the Swedish muta-
tion, and they developed AD-like features such as memory 
defi  cits and Aβ plaques in the brain (17, 18). The amyloid 
plaques began to accumulate in the brains of Tg2576 mice 
around the age of 9 mo, when the AD-like features started to 
develop (17). We initially checked the brains of 12-mo-old 
Tg2576 mice for the existence of Aβ aggregates and their 
learning/memory capabilities. Indeed, the Tg2576 mouse 
brains contained Aβ depositions throughout the cortex (Fig. 
3 A) and hippocampus (Fig. 3 B). These Tg2576 mice also 
exhibited signifi  cantly impaired learning/memory in the 
  water maze test (compare the latencies of WT®PBS with 
Tg2576®PBS from session 1; Fig. 3 C). The Tg2576 mice 
were then treated with PBS or G-CSF, respectively, for 5 d. 
As shown in Fig. 3 C, although the latencies were similar be-
tween the wild-type mice treated with G-CSF and PBS, re-
spectively, throughout the test (sessions 1–6; Fig. 3 C), G-CSF 
treatment signifi   cantly reduced the latency of the Tg2576 
mice when compared with the PBS-treated controls (Fig. 3 C). 
Similar to the experiments with the Aβ injection AD model, 
the G-CSF treatment also signifi  cantly increased the number 
of BrdU+-proliferating cells in the damaged brains of Tg2576 
mice (Fig. 3 D), which were spread throughout the cortex 
Figure 2.  Stimulated increase of BrdU+ cells by G-CSF. (A) WBC 
counts of AD mice administrated with PBS or G-CSF. The WBC counts 
were analyzed for mice after their treatment for 5 d with PBS or G-CSF 
(n = 8 for each group). (B and C) Immunostaining for BrdU+ cells in a coro-
nal brain section after BrdU incorporation of AD mice treated with G-CSF. 
The boxed area in B is magnifi  ed in C. The arrows indicate the injection 
site. Bar, 100 μm. (D) Comparison of the average numbers of BrdU+ cells 
in the hemispheres of AD mice receiving BrdU and treated with PBS or 
G-CSF for 5 d (n = 5 for each group). The cell numbers were determined by 
immunostaining with anti-BrdU, as represented in B and C. (E) Distance 
dependence of the distribution of BrdU+ cells. The numbers of BrdU+ cells 
at different distances radially from the injection sites of the individual AD 
mice treated with G-CSF or PBS for 5 d and incorporated with BrdU were 
counted in the confocal microscope and averaged (n = 5 for each group). 
(F) Double immunostaining of BrdU and CD34. The brain sections from 
the AD mice with G-CSF treatment and BrdU incorporation were double 
stained with anti-BrdU (green) and anti-CD34 (red). Bar, 100 μm. Data in 
A, D, and E are means ± SEM. *, P < 0.05. DG, dentate gyrus.1276  G-CSF RESCUES THE MEMORY IMPAIRMENT | Tsai et al.
and hippocampus (not depicted). Thus, G-CSF also appeared 
to be an eff  ective agent in rescuing the cognitive function of 
mice with a chronic pattern of AD development.
G-CSF–enhanced neurogenesis and the level of brain 
acetylcholine (ACh)
To examine the proportion of neuronal cells among the 
BrdU+ cells in the brains of G-CSF–treated AD mice, double 
immunostaining was performed. For this, we used two addi-
tional antibodies directed against the microtubule-associated 
protein 2 (MAP2) and the vertebrate neuron-specifi  c nuclear 
protein (NeuN), respectively. Both proteins are markers for 
most of the neuronal cell types throughout the mouse nervous 
system, including the cerebral cortex and the hippocampus 
(19). Single-section analysis of the immunostaining patterns 
of the acute AD mice, as represented in Fig. 4 (A–H), and 
Tg2576 mice (not depicted), as well as a three-dimensional 
reconstruction of multiple confocal images (not depicted), 
indicated that  40% of the BrdU+ cells coexpressed NeuN 
(Fig. 4, I and J) or MAP2 (not depicted). These percent-
ages are higher than those ( 20%) of the PBS-treated con-
trol mice (Fig. 4, I and J). These data suggested that G-CSF 
treatment caused an accumulation of proliferating, neuronal 
cells around the damaged brain areas of the AD mice. These 
cells very likely contributed to the rescue of the cognitive 
functions of both the acute, Aβ-induced AD mice and the 
Tg2576 mice by improving their neuronal plasticity.
To identify the molecular basis for the rescue of cognitive 
function by G-CSF, we analyzed the levels of ACh, as well as 
Aβ, in the brains of Tg2576 mice, with or without treatment 
by G-CSF. As shown in Fig. 5 A, G-CSF treatment increased 
the level of ACh by  20% when compared with the un-
treated Tg2576 mice and PBS-treated controls, respectively. 
In addition, we used both ELISA and immunohistochemistry 
to analyze the eff  ect of G-CSF on the extent of brain amyloid 
aggregation. As shown in Fig. 5 B, there were no signifi  cant 
changes in the levels of both the SDS-soluble Aβ and the 
SDS-insoluble Aβ aggregates in the brains of Tg2576 mice 
treated with either PBS or G-CSF. Furthermore, the Aβ 
plaque burden in either the hippocampus or the cortex was 
similar among the G-CSF–treated, PBS-treated, and untreated 
Tg2576 mice (Fig. 5, C and D).
To examine whether the therapeutic eff  ect of G-CSF could 
persist for a longer period of time, we analyzed the cognitive 
functions of Tg2576 mice 3 mo after the treatment. For this, 
10 12-mo-old mice were divided into two groups and subjected 
to the water maze test before and 3 mo after subcutaneous 
administration with PBS and G-CSF, respectively (see Materials 
and methods). As shown in Fig. 5 E, the average latencies 
of the Tg2576 mice were similarly high with (Tg2576®PBS 
3 mo) and without (Tg2576®PBS control) the PBS treatment. 
On the other hand, the G-CSF–treated mice remarkably showed 
a signifi  cantly better learning/memory capability even at 3 mo 
after the treatment (compare Tg2576®G-CSF 3 mo with 
Figure 3.  Rescue of the cognitive function of Tg2576 by G-CSF 
treatment. (A and B) Immunostaining of Aβ aggregates (brown) in the 
cortex (A) and hippocampus (B) of a 12-mo-old Tg2576 mouse. Bars, 200 
μm. (C) The cognitive function of Tg2576 mice after subcutaneous ad-
ministration of PBS or G-CSF was tested by the water maze learning task. 
The latencies from the tests of the wild-type control mice treated with 
PBS or G-CSF are included for comparison (n = 9 for the Tg2576®G-CSF 
group; n = 7 for the other three groups). The test data of one mouse 
unresponsive to the G-CSF treatment was not included in this fi  gure. 
(D) Average numbers of BrdU+ cells, as determined by anti-BrdU immuno-
staining, in the hemispheres of Tg2576 mice receiving BrdU and treated 
with PBS or G-CSF for 5 d (n = 5 for each group). Data are means ± 
SEM. *, P < 0.05. CA1, hippocampal CA1 layer; CA3, hippocampal CA3 
layer; CX, cortex; DG, dentate gyrus; LV, lateral ventricle.JEM VOL. 204, June 11, 2007  1277
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Tg2576®G-CSF control; Fig. 5 E). The data in Fig. 5 E in-
dicated that administration of G-CSF could exert a long-
  lasting eff  ect on the rescue of the cognitive functions of the 
Tg2576 AD mice.
One or a combination of the following could explain the 
cellular basis for rescue of the learning/memory defi  ciency in 
AD mice by G-CSF. First, similar to that proposed for the 
G-CSF eff  ect on mice with ischemic heart disease or cerebral 
ischemia/stroke (8, 11), G-CSF could induce mobilization of 
bone marrow–derived HSCs that invaded the mouse brain 
  areas damaged by the Aβ aggregates. As suggested by the 
signi  fi  cant increases of BrdU+/NeuN+ and BrdU+/MAP2+ 
cells near the Aβ aggregates in the brains of the acute AD mice 
or in the cortex/hippocampus of Tg2576 mice (Figs. 2 and 4), 
the HSCs diff  erentiated into neuronal cells, thus leading to the 
functional and structural recovery of the brains of AD mice. 
Further, the fact that at least a portion (20%) of the BrdU+ 
cells in the brains from an acute AD mouse model treated with 
G-CSF were also CD34+, as exemplifi  ed in Fig. 2 F, provided 
the fi  rst direct evidence for G-CSF–induced mobilization of 
HSCs into the damaged brain regions. The diff  erent cytokines 
and trophic factors produced by HSCs within the cerebral 
  tissue or within the microvasculature of an injured brain could 
also stimulate the proliferation, migration, and diff  erentiation 
of neuronal progenitor cells (20–22), thus contributing to the 
functional and structural recoveries of the damaged brain.
Second, neuronal stem cells (NSCs) have been shown to 
reside in several regions in the adult brain, and they give rise 
to mature neuronal cells (23). Interestingly, G-CSF could 
  induce the diff  erentiation of NSCs in vitro, and this eff  ect 
paralleled the in vivo fi  nding that G-CSF also induced neuro-
genesis and subsequently enhanced functional recovery after 
cortical cerebral ischemia (12). Thus, G-CSF might also have 
enhanced the neurogenesis of NSCs near the Aβ aggregates 
and/or damaged brain regions of the AD mice. Finally, part 
of the rescuing eff  ect of G-CSF on the AD mice might be 
caused by a direct protective role of G-CSF against programmed 
death of the neurons (24).
Notably, the treatment of patients with AD has been 
based largely on a strategy of enhancing the ACh-mediated 
transmission. Symptomatic benefi  ts (cognitive, functional, 
and behavioral) have been observed in multiple clinical trials 
with agents known to inhibit acetylcholinesterase, which ca-
talyses the breakdown of ACh. Our data in Fig. 5 A sug-
gested that the rescue of the cognitive function of Tg2576 by 
G-CSF mice was partly caused by the increased level of ACh, 
Figure 4.  Enhancement of neurogenesis in AD mice by G-CSF. 
(A–H) Brain sections of the acute AD mice treated with G-CSF were 
double stained with anti-BrdU/anti-MAP2 (A–D) or with anti-BrdU/anti-
NeuN (E–H). A and E provide low-magnifi  cation pictures of the staining 
patterns. The boxed areas in A and E are magnifi  ed in B–D and F–H, 
  respectively. The arrows point to one example each of BrdU+/MAP2+ 
and BrdU+/NeuN+ cells. Bars, 50 μm. (I and J) Comparisons of the 
average percentages of NeuN+/BrdU+ cells in the hemispheres of Aβ-
induced AD mice (I) or Tg2576 mice (J) treated with PBS or G-CSF 
for 5 d (n = 5 for each group). The cell numbers were determined by 
immunostaining, as represented in A–H. Data are means ± SEM. DG, 
dentate gyrus.1278  G-CSF RESCUES THE MEMORY IMPAIRMENT | Tsai et al.
likely as the result of a release of ACh from cholinergic neu-
rons in the population of newly generated neuronal cells, as 
stimulated by G-CSF.
Our data have suggested the feasibility of using G-CSF as 
a novel therapeutic strategy for the treatment of AD. When 
compared with the drugs previously applied to Aβ-induced 
Figure 5.  Effects of G-CSF treatment on the brain levels of ACh 
and A𝗃. (A) Extents of ACh release in the brains of Tg2576 mice after 
subcutaneous administration with PBS or G-CSF. The extents are ex-
pressed as the percentages of the brain ACh level of the wild-type mice 
(n = 5 for each group). Note the relatively lower level of ACh in the 
brains of Tg2576 mice compared with the wild type, as well as the sig-
nifi  cant increase of the brain ACh amount of Tg2576 upon treatment 
with G-CSF but not with PBS. *, P < 0.05. (B) The levels of SDS-soluble 
Aβ (SDS-Aβ, left) and SDS-insoluble/formic acid–soluble Aβ (FA-Aβ, 
right) in the brains of untreated Tg2576 mice in comparison with Tg2576 
mice after subcutaneous administration with PBS or G-CSF (n = 5 for 
each group). Note the insignifi  cant differences among the three groups 
(P > 0.1 according to the Student’s t test). (C and D) The Aβ plaque bur-
den in the brains of untreated Tg2576 mice in comparison with Tg2576 
mice after subcutaneous administration with PBS or G-CSF. The distribu-
tion patterns of the Aβ plaques in the hippocampus of PBS- and G-CSF–
treated Tg2576 mice, respectively, are represented in C. Bars, 200 μm. 
The quantitative image analysis of the total areas of the Aβ plaque 
  burden in the hippocampus or cortex of untreated, PBS-treated, and 
G-CSF–treated Tg2576 mice, respectively, is shown in D (n = 3 for each 
group). Note the insignifi  cant differences among the three groups (P > 
0.1 according to the Student’s t test). (E) Long-lasting effect of G-CSF 
rescue of Tg2576 mice. The water maze test was applied to measure 
the cognitive functions of Tg2576 mice 3 mo after the subcutaneous 
administration of PBS or G-CSF. The latencies of the Tg2576 mice before 
the treatment with PBS or G-CSF (the controls) are included for com-
parison (n = 5 for each group). Data in A, B, D, and E are means ± SEM. 
*, P < 0.05.JEM VOL. 204, June 11, 2007  1279
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AD animal models (e.g., ferulic acid [15] and cannabinoids 
[25]), the rescuing eff  ect of G-CSF in the behavior test is at 
least equal. G-CSF is also as eff  ective as other therapies such 
as the use of Aβ antibody (26). Notably, our data in Fig. 5 E 
showed that the rescuing eff  ect of G-CSF may be long-
  lasting. We propose that G-CSF treatment of human AD pa-
tients would also mobilize autologous HSCs into circulation, 
enhance their translocation into the damaged brains, substan-
tially repair the lesion areas, and, thus, rescue the memory 
dysfunction of the patients. The noninvasive nature of G-CSF 
treatment, when compared with the common practice of 
stem cell transplantation, makes it a potentially ideal AD drug 
for clinical trials. The combination of G-CSF with one or more 
of the other therapeutic ways would be another perspective 
direction for AD treatment.
MATERIALS AND METHODS
AD mouse models. Two diff  erent mouse models of AD were generated 
and/or bred for the test of G-CSF therapy. The acute Aβ-induced model 
was generated according to a previously described protocol (14, 15). 8-wk-
old C57BL/6 male mice were purchased from the National Laboratorial 
Animal Center and bred at the Animal Facility of the Institute of Molecular 
Biology (IMB) at Academia Sinica. Experimental procedures for handling 
the mice followed the guidelines of the IMB. Animals were housed in a 
room maintained on a 12-h/12-h light/dark cycle (light on at 7:00 a.m.). 
The Aβ aggregate was prepared from a solution of 10 mM of soluble Aβ(1–42) 
(Sigma-Aldrich) in 0.01 M PBS, pH 7.4. The solution was incubated at 
37°C for 3 d to form the aggregated Aβ and stored at −70°C. Animals were 
intraperitoneally anesthetized with 40 mg/kg sodium pentobarbital, and the 
injection of aggregated Aβ was made bilaterally into the dorsal hippocampus 
using a 26-gauge needle connected to a microsyringe (Hamilton). The ani-
mals were subjected to stereotaxic surgery with the incisor bar set at the fol-
lowing coordinates: 2 mm posterior to the bregma, 2.1 mm bilateral to the 
midline, and 1.8 mm ventral to the skull surface. The volume of injection 
was 1 μl of aggregated Aβ or 1 μl PBS, and 7 d were allowed for AD symp-
toms to develop in the subjects. For the chronic AD model, Tg2576 mice 
were purchased from Taconic and were bred as described in this section.
G-CSF treatment. For the acute AD model, 7 d after injection of the ag-
gregated Aβ, mice were subcutaneously injected with 50 μg/kg of re-
combinant human G-CSF (Amgen Biologicals) once daily for 5 consecutive 
days (7, 11). The control animals were injected with PBS in parallel. More 
details are described in Fig. 1 A. Tg2576 mice were treated in a similar way.
Behavioral measurements. For spatial learning in the Morris water maze 
learning task, which was used as previously described (27), the animals were 
subjected to four trials per session and two sessions per day, with one session 
given in the morning and the other given in the afternoon. For a complete 
test, a total of six sessions over 3 d were given. In each of the four trials, the 
animals were placed at four diff  erent starting positions equally spaced around 
the perimeter of the pool in a random order. They were allowed 120 s to 
fi  nd the platform. If an animal could not fi  nd the platform in 120 s, it was 
guided to the platform. After mounting the platform, the animals were al-
lowed to stay there for 20 s. The time that an individual mice took to reach 
the platform was recorded as the escape latency. For all the behavior tests in 
this study, the native mice received the spatial training for six sessions over 
3 d to learn the location of a submerged platform in the pool. 7 d after the Aβ 
injection, the water maze test (six sessions over 3 d) was used to confi  rm the 
AD symptoms. The same water maze test was also used to check the behav-
ioral performances of mice after G-CSF or PBS treatment. For Aβ-injected 
mice, the waiting period before the test was 14 d after the fi  rst injection (Fig. 
1 E). For Tg2576 mice, the waiting period was either 14 d (Fig. 3 C) or 
3 mo (Fig. 5 E).
BrdU labeling. BrdU (Sigma-Aldrich), a thymidine analogue that is incor-
porated into the DNA of dividing cells during S phase, was used for mitotic 
labeling. The labeling protocol followed those previously described (28). A 
cumulative labeling method was used to examine the population of prolifer-
ative cells, with the mice receiving daily intraperitoneal injections of 50 mg/
kg BrdU for 16 consecutive days, starting on the fi  rst day of G-CSF injec-
tion. The BrdU+ cells in both hemispheres of the hippocampus and cortex 
were digitally counted with the use of a 20× objective lens with a laser scan-
ning confocal microscope (LSM510; Carl Zeiss MicroImaging, Inc.) via a 
computer imaging analysis system (Imaging Research). For each animal, 40 
coronal sections (each 15-μm thick) throughout the hippocampus and cor-
tex were analyzed. The image analysis was also used to examine the distribu-
tions of BrdU+ cells radially surrounding the Aβ aggregates that formed near 
the microinjection sites.
Immunohistochemistry. Immunohistostaining was used to identify the 
locations of BrdU and diff  erent proteins in the mouse brain. Double immu-
nofl   uorescence staining was performed to identify MAP2, NeuN, and 
CD34, respectively, in BrdU+ cells. For this, the mouse monoclonal anti-
BrdU (Chemicon) and Alex Fluor 488–conjugated goat anti–mouse anti-
bodies (Invitrogen) were initially used, followed by treatment with the rabbit 
polyclonal anti-MAP2 (Chemicon) and Alex Fluor 555–conjugated donkey 
anti–rabbit antibodies (Invitrogen) for the identifi   cation of the neuronal 
dendrites. Alternatively, the anti-BrdU and Alex Fluor 555–conjugated don-
key anti–mouse antibodies (Invitrogen) were used, followed by treatment 
with rabbit polyclonal Alex Fluor 488–conjugated anti-NeuN (Chemicon) 
antibodies to identify the neuronal nuclei. The rabbit polyclonal anti-CD34 
(Serotec) and Alex Fluor 555–conjugated donkey anti–rabbit antibodies 
were used to identify HSCs. For thiofl  avin S staining (29), the brain sections 
were fi  xed to the slides with 4% formaldehyde in 0.1 M phosphate buff  er 
and stained with 1% thiofl  avin S (Sigma-Aldrich) solution for 8 min. Sec-
tions were rapidly washed once in 100% ethanol and twice in 80% ethanol/
water, rinsed for 10 min with water, and mounted with the mounting 
  medium. All immunostaining sections were analyzed with a laser scanning 
confocal microscope. The green (Alex Fluor 488) and red (Alex Fluor 
555) fl  uorochromes on the slides were excited by a laser beam at 488 and 
543 nm, respectively.
ACh assay. For measuring ACh levels in the mouse brains, the mice were 
killed, and their brains were quickly removed and frozen on dry ice. The 
brains were homogenized on ice and immediately subjected to the ACh 
  assay. The ACh levels in the brain extracts were then determined with the 
Amplex Red Acetylcholine/Acetylcholinesterase Assay Kit (Invitrogen), ac-
cording to the manufacturer’s instructions. The measurement was performed 
in a fl  uorescence microplate reader (PowerWave 340; BioTek) using excita-
tion in the range of 530–560 nm and emission detection at 590 nm.
Quantifi  cations of the A𝗃 levels and A𝗃 plaque burden. The levels of 
soluble and insoluble Aβ were quantifi  ed according to the procedures of 
Kawarabayashi et al. (30). The tissue samples were homogenized in 10 wet-
weight volumes of PBS containing a cocktail of protease inhibitors (20 μg/
ml each of pepstatin A, aprotinin, phosphoramidon, and leupeptin; 0.5 mM 
PMSF; and 1 mM EGTA). The samples were briefl  y sonicated (10 W, 2 × 
5 s) and centrifuged at 100,000 g for 20 min at 4°C. The soluble fraction (su-
pernatant) was used for the Aβ ELISA assay. To quantitate the insoluble 
Aβ/Aβ aggregates, the SDS-insoluble pellet was sonicated and dissolved in 
70% formic acid. The extract was neutralized with 0.25 M Tris, pH 8, con-
taining 30% acetonitrile and 5 M NaOH before loading onto an ELISA 
plate. The protein-containing samples were subjected to assay by the Aβ 
ELISA kit (Sigma-Aldrich), and the signals at 450 nm were detected using a 
multiwell plate reader.
To quantify the Aβ plaque burden in the mouse brains, the method 
of Janus et al. (26) was followed. Eight sections from each cerebral hemi-
sphere were immunostained with anti-Aβ antibody (Chemicon) and visual-
ized with diaminobenzidine. The plaque burden was analyzed using ImageJ 1280  G-CSF RESCUES THE MEMORY IMPAIRMENT | Tsai et al.
software (National Institutes of Health), the brain area (hippocampus or 
  cortex) was outlined, and the area and number of plaques in the outlined 
structure were recorded.
Statistical analysis. Data are reported as means ± SEM. Independent ex-
periments were compared using the Student’s t test. Diff  erences, indicated 
by asterisks, were considered statistically signifi  cant at P < 0.05.
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